Royalty Pharma (NASDAQ:RPRX) and Aditxt (NASDAQ:ADTX) Financial Comparison
by Kim Johansen · The Markets DailyAditxt (NASDAQ:ADTX – Get Free Report) and Royalty Pharma (NASDAQ:RPRX – Get Free Report) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, earnings, dividends, valuation, profitability and analyst recommendations.
Insider and Institutional Ownership
15.5% of Aditxt shares are held by institutional investors. Comparatively, 54.3% of Royalty Pharma shares are held by institutional investors. 0.0% of Aditxt shares are held by company insiders. Comparatively, 18.8% of Royalty Pharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Risk & Volatility
Aditxt has a beta of 1.34, meaning that its stock price is 34% more volatile than the S&P 500. Comparatively, Royalty Pharma has a beta of 0.42, meaning that its stock price is 58% less volatile than the S&P 500.
Analyst Ratings
This is a breakdown of recent recommendations for Aditxt and Royalty Pharma, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Aditxt | 1 | 0 | 0 | 0 | 1.00 |
| Royalty Pharma | 0 | 0 | 8 | 0 | 3.00 |
Royalty Pharma has a consensus target price of $61.57, suggesting a potential upside of 1.00%. Given Royalty Pharma’s stronger consensus rating and higher possible upside, analysts plainly believe Royalty Pharma is more favorable than Aditxt.
Valuation & Earnings
This table compares Aditxt and Royalty Pharma”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Aditxt | $14,336.00 | 0.07 | -$41.71 million | ($100,788.35) | -0.00 |
| Royalty Pharma | $2.54 billion | 13.82 | $770.95 million | $1.45 | 42.04 |
Royalty Pharma has higher revenue and earnings than Aditxt. Aditxt is trading at a lower price-to-earnings ratio than Royalty Pharma, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Aditxt and Royalty Pharma’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Aditxt | -360,152.50% | -374.60% | -105.93% |
| Royalty Pharma | 32.14% | 30.01% | 14.91% |
Summary
Royalty Pharma beats Aditxt on 13 of the 14 factors compared between the two stocks.
About Aditxt
Aditxt, Inc., a biotech company, engages in the development and commercialization of technologies that focus on improving the health through monitoring and modulating the immune systems. The company develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its tissues. It also develops ADI-100 for skin grafting, psoriasis, type 1 diabetes, and multiple sclerosis. Aditxt, Inc. has a license agreement with Loma Linda University and Leland Stanford Junior University. The company was formerly known as ADiTx Therapeutics, Inc. and changed its name to Aditxt, Inc. in July 2021. Aditxt, Inc. was incorporated in 2017 and is headquartered in Richmond, Virginia.
About Royalty Pharma
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 commercial products and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, immunology, respiratory, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.